Ashwini Balakrishnan, Ph.D. - Publications

Affiliations: 
2013 Cellular and Molecular Pathology University of Pittsburgh, Pittsburgh, PA, United States 
Area:
Human Development, Cell Biology, Molecular Biology

9 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Balakrishnan A, Rajan A, Salter AI, Kosasih PL, Wu Q, Voutsinas J, Jensen MC, Plückthun A, Riddell S. Multispecific targeting with synthetic ankyrin repeat motif chimeric antigen receptors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31548346 DOI: 10.1158/1078-0432.Ccr-19-1479  0.537
2019 Specht J, Lee S, Turtle C, Berger C, Balakrishnan A, Srivastava S, Viollet V, Veatch J, Gooley T, Mullane E, Chaney C, Rader C, Pierce R, Gottardo R, Maloney D, et al. Abstract P2-09-13: A phase I study of adoptive immunotherapy for ROR1+ advanced triple negative breast cancer (TNBC) with defined subsets of autologous T cells expressing a ROR1-specific chimeric antigen receptor (ROR1-CAR) Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-P2-09-13  0.497
2018 Balakrishnan A. CAR-T Cells: Next Generation Cancer Therapeutics Journal of the Indian Institute of Science. 98: 21-31. DOI: 10.1007/S41745-018-0062-8  0.557
2017 Balakrishnan A, Salter AI, Plückthun A, Riddell SR. Abstract A75: Designed Ankyrin Repeat Proteins (DARPins) as recognition motifs in chimeric antigen receptors Cancer Immunology Research. 5. DOI: 10.1158/2326-6074.Tumimm16-A75  0.53
2016 Balakrishnan A, Goodpaster T, Randolph-Habecker J, Hoffstrom BG, Jalikis FG, Koch LK, Berger C, Kosasih PL, Rajan A, Sommermeyer D, Porter P, Riddell SR. Analysis of ROR1 protein expression in human cancer and normal tissues. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27852699 DOI: 10.1158/1078-0432.Ccr-16-2083  0.503
2015 Berger C, Sommermeyer D, Hudecek M, Berger M, Balakrishnan A, Paszkiewicz PJ, Kosasih PL, Rader C, Riddell SR. Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells. Cancer Immunology Research. 3: 206-16. PMID 25355068 DOI: 10.1158/2326-6066.Cir-14-0163  0.561
2014 Riddell SR, Sommermeyer D, Berger C, Liu LS, Balakrishnan A, Salter A, Hudecek M, Maloney DG, Turtle CJ. Adoptive therapy with chimeric antigen receptor-modified T cells of defined subset composition. Cancer Journal (Sudbury, Mass.). 20: 141-4. PMID 24667960 DOI: 10.1097/Ppo.0000000000000036  0.483
2014 Berger SC, Sommermeyer D, Hudecek M, Berger M, Balakrishnan A, Paskiewicz P, Kosasih P, Rader C, Riddell S. Safety of targeting ROR1 for cancer immunotherapy with chimeric antigen receptor-modified T cells in a primate model Journal For Immunotherapy of Cancer. 2. DOI: 10.1186/2051-1426-2-S3-P3  0.59
2013 Balakrishnan A, Chaillet JR. Role of the inositol polyphosphate-4-phosphatase type II Inpp4b in the generation of ovarian teratomas. Developmental Biology. 373: 118-29. PMID 23078915 DOI: 10.1016/J.Ydbio.2012.10.011  0.358
Show low-probability matches.